Adrenal Function and Use of Intralesional Triamcinolone Acetonide 10 mg/mL (Kenalog-10) in Patients With Alopecia Areata

NCT ID: NCT00484679

Last Updated: 2018-06-29

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 18 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2007-05-31
• Study Completion Date: 2011-03-31

Brief Summary

The purpose of the study is to see whether treating alopecia areata with injections of the corticosteroid, Triamcinolone acetonide 10mg/cc (Kenalog-10), has an impact on the adrenal glands.

Detailed Description

1. To determine the effects of intralesional Triamcinolone Acetonide 10mg/cc (Kenalog 10) use for the treatment of alopecia areata on adrenal function.

2. To evaluate the efficacy of intralesional corticosteroids (Kenalog-10)on hair regrowth in moderate to severe alopecia areata.

18 subjects with moderate to severe alopecia areata were enrolled and 15 subjects completed all study visits.

Subjects underwent intralesional triamcinolone acetonide (10mg/cc) (Kenalog-10) injections every 6 weeks for a period of 6 months in the General Clinical Research Center (GCRC). This period was followed by a 6 week, injection-free, safety follow-up visit. Adrenal function was assessed by utilization of the Low Dose Adrenocorticotropic Hormone Stimulation Test (ACTH) which measures adrenal gland production of cortisol after exogenously administered ACTH. Serum blood draws of 3 mL were done at baseline and 6-week intervals at the start of each scheduled appointment for intralesional treatment at approximately 0800 hours. Two blood draws were taken at time 0 and again 30 minutes after a 1 mcg bolus dose of synthetic ACTH (Cortrosyn).

Patients underwent their scheduled course of intralesional corticosteroid (Kenalog-10) injections and other study data was collected, such as SALT scores and physician assessments of AA, during the time between blood draws.

Conditions

Alopecia Areata

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: SCREENING
• Blinding Strategy: NONE

Study Groups

1

Patients receiving Triamcinolone Acetonide 10 ml (Kenalog-10) intralesional injections.

Group Type: EXPERIMENTAL

Triamcinolone Acetonide 10 mg/mL (Kenalog-10)

Intervention Type: DRUG

Triamcinolone Acetonide 10 mg/ml (Kenalog-10) intralesional injection

Interventions

Triamcinolone Acetonide 10 mg/mL (Kenalog-10)

Triamcinolone Acetonide 10 mg/ml (Kenalog-10) intralesional injection

Intervention Type: DRUG

Other Intervention Names

Kenalog 10

Eligibility Criteria

Inclusion Criteria

• Subject has clinical diagnosis of alopecia areata.
• Written informed consent and HIPAA authorization have been obtained.

• Female subjects of childbearing potential have a negative pregnancy test and agree to use an acceptable method of birth control to prevent pregnancy.
• In the opinion of the investigator, subject is a candidate for intralesional therapy for alopecia areata.
• Subject agrees to comply with protocol requirements and attend all required study visits and is considered to be a good study subject.
• Subject meets concomitant medication washout requirements.
• Subject is >/= 18 years of age.

Exclusion Criteria

• Subject has alopecia universalis.
• Subject has known adrenocortical insufficiency or Cushing's Syndrome.
• Subject is pregnant or lactating.
• Subject has current controlled or uncontrolled bacterial, viral, fungal, atypical, or opportunistic infections.
• Subject possesses hypersensitivity to cortrosyn or Triamcinolone Acetonide (Kenalog-10) or any component of their formulation.
• Subject is currently or has undergone therapy for malignancy within the past five years.
• Subject has history of substance abuse within the past five years.
• Subject has used oral corticosteroids within the past 12 months.
• Subject has concurrent use of phenytion rifampin, phenobarbital, mitotane, or other formulations of corticosteroid medications.
• Subject has any medical condition that, in the judgement of the investigator, would jeopardize the subject's safety following exposure to the administered medications.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

National Alopecia Areata Foundation

OTHER

Sponsor Role: collaborator

University of Minnesota

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Maria K Hordinsky, MD

Role: STUDY_DIRECTOR

University of Minnesota

Locations

University of Minnesota

Minneapolis, Minnesota, United States

Countries

United States

Other Identifiers

0609M91989

Identifier Type: -

Identifier Source: org_study_id